DE69527202T2 - Proteinartige adjuvantien - Google Patents
Proteinartige adjuvantienInfo
- Publication number
- DE69527202T2 DE69527202T2 DE69527202T DE69527202T DE69527202T2 DE 69527202 T2 DE69527202 T2 DE 69527202T2 DE 69527202 T DE69527202 T DE 69527202T DE 69527202 T DE69527202 T DE 69527202T DE 69527202 T2 DE69527202 T2 DE 69527202T2
- Authority
- DE
- Germany
- Prior art keywords
- immune response
- modulated immune
- alum
- genetically
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25822894A | 1994-06-10 | 1994-06-10 | |
US258228 | 1994-06-10 | ||
PCT/CA1995/000341 WO1995034323A2 (en) | 1994-06-10 | 1995-06-08 | Proteinaceous adjuvants |
Publications (3)
Publication Number | Publication Date |
---|---|
DE69527202D1 DE69527202D1 (de) | 2002-08-01 |
DE69527202T2 true DE69527202T2 (de) | 2002-12-05 |
DE69527202T3 DE69527202T3 (de) | 2008-07-31 |
Family
ID=22979642
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69535943T Expired - Lifetime DE69535943D1 (de) | 1994-06-10 | 1995-06-08 | Proteinartige Adjuvantien |
DE69527202T Expired - Lifetime DE69527202T3 (de) | 1994-06-10 | 1995-06-08 | Proteinartige adjuvantien |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69535943T Expired - Lifetime DE69535943D1 (de) | 1994-06-10 | 1995-06-08 | Proteinartige Adjuvantien |
Country Status (10)
Country | Link |
---|---|
US (2) | US20030072774A1 (de) |
EP (3) | EP0764029B2 (de) |
AT (2) | ATE429928T1 (de) |
AU (1) | AU2876595A (de) |
CA (1) | CA2192454A1 (de) |
DE (2) | DE69535943D1 (de) |
DK (2) | DK1149589T3 (de) |
ES (2) | ES2325475T3 (de) |
PT (2) | PT764029E (de) |
WO (1) | WO1995034323A2 (de) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9513371D0 (en) | 1995-06-30 | 1995-09-06 | Biocine Spa | Immunogenic detoxified mutant toxins |
DE69434000T3 (de) | 1993-10-05 | 2008-11-06 | UCB Pharma Ltd., Slough | Impfstoffzusammensetzungen |
GB9326174D0 (en) * | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
US20030072774A1 (en) * | 1994-06-10 | 2003-04-17 | Diane M. Gajewczyk | Proteinaceous adjuvants |
GB9500788D0 (en) * | 1995-01-16 | 1995-03-08 | Medeva Holdings Bv | Vaccine compositions |
US6020182A (en) | 1996-07-12 | 2000-02-01 | Connaught Laboratories Limited | Subunit respiratory syncytial virus vaccine preparation |
GB9622660D0 (en) | 1996-10-31 | 1997-01-08 | Biocine Spa | Immunogenic detoxified mutant toxin |
US6818222B1 (en) * | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
EP1486215A3 (de) * | 1997-03-21 | 2006-04-12 | Chiron Corporation | Detoxifizierte Mutanten bakterieller ADP-ribosylierender Toxine als parenterale Adjuvantien |
DE69939943D1 (de) * | 1998-10-21 | 2009-01-02 | Kitasato Inst | Attenuierte Toxine als Adjuvantien |
ATE422364T1 (de) | 1998-12-17 | 2009-02-15 | Sanofi Pasteur Ltd | Multivalente immunogenische zusammensetzung, die eine rsv untereinheit zusammensetzung und ein influenzavirus präparat enthält |
US7115730B1 (en) | 1999-04-27 | 2006-10-03 | Chiron Srl | Immunogenic detoxified mutant E. coli LT-A-toxin |
AU1013601A (en) | 1999-10-22 | 2001-05-08 | Aventis Pasteur Limited | Method of inducing and/or enhancing an immune response to tumor antigens |
EP1792995A3 (de) | 2000-05-08 | 2007-06-13 | Sanofi Pasteur Limited | Chlamydia Antigene, entsprechende DNS Fragmente und ihre Verwendungen |
DK1282702T3 (da) | 2000-05-10 | 2007-04-02 | Sanofi Pasteur Ltd | Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf |
ATE357461T1 (de) | 2000-08-25 | 2007-04-15 | Aventis Pasteur | Innen-kern oligosaccharide epitopes aus lipopolysacchariden von haemophilus influenza als vakzinen in der prophylaktischen behandlung von haemophilus influenzae infektionen |
AU2002322380B2 (en) * | 2001-06-07 | 2006-11-02 | Government Of The United States Of America As Represented By The Uniformed Services University Of The Health Sciences | Mutant forms of cholera holotoxin as an adjuvant |
DE60234695D1 (de) | 2001-06-07 | 2010-01-21 | Univ Colorado | Mutantenformen von cholera holotoxin als adjuvans |
EP2502999A3 (de) | 2006-03-03 | 2013-01-23 | Amorfix Life Sciences Ltd. | Verfahren und Zusammensetzungen zum Behandeln und Erkennen von missgefaltetem SOD 1-herbeigeführte Erkrankungen |
CN101688194B (zh) | 2007-05-23 | 2013-09-11 | Uab研究基金会 | 去毒的肺炎球菌神经氨酸酶及其用途 |
CA2941174C (en) | 2007-09-11 | 2018-05-08 | University Of Guelph | Novel polysaccharide immunogens from clostridium difficile |
WO2009039125A1 (en) * | 2007-09-17 | 2009-03-26 | The Schepens Eye Research Institute, Inc. | Use of ocular neuropeptides as immune adjuvants |
US8210944B2 (en) * | 2007-10-29 | 2012-07-03 | Igt | Gaming system having display device with changeable wheel |
JP5070006B2 (ja) * | 2007-11-02 | 2012-11-07 | 株式会社オハラ | 結晶化ガラス |
MX2011006922A (es) | 2008-12-24 | 2012-06-12 | Netherlands Vaccine Inst | Polipeptidos de neumolisina (ply) modificada a partir de streptococcus pneumonia. |
WO2012101509A2 (en) | 2011-01-28 | 2012-08-02 | Sanofi Pasteur Sa | Immunological compositions against hiv |
JP5966018B2 (ja) * | 2011-12-21 | 2016-08-10 | バイオネット−エイジア,カンパニー・リミテッド | 改変ボルデテラ・パータシス株 |
WO2014140938A2 (en) | 2013-03-14 | 2014-09-18 | Centre Hospitalier Universitaire Vaudois | Immunological methods |
KR20180085736A (ko) | 2015-11-09 | 2018-07-27 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 아밀로이드 베타 중간-영역 내 에피토프 및 이에 대해 구조적으로 선택성인 항체 |
WO2017079831A1 (en) | 2015-11-09 | 2017-05-18 | The University Of British Columbia | N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto |
KR20180094876A (ko) | 2015-11-09 | 2018-08-24 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 아밀로이드 베타 에피토프 및 이에 대한 항체 |
US20180125920A1 (en) | 2016-11-09 | 2018-05-10 | The University Of British Columbia | Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions |
IT201900007060A1 (it) | 2019-05-21 | 2020-11-21 | St Superiore Di Sanita | Cellule tumorali ingegnerizzate e loro usi |
IT201900012540A1 (it) | 2019-07-22 | 2021-01-22 | Humanitas Mirasole Spa | Inibitori di CHI3L1 e loro usi |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2144129B (en) * | 1981-08-24 | 1985-10-09 | Vilas V Likhite | Antigens as immunostimulant adjuvants |
WO1989001976A1 (en) * | 1987-09-04 | 1989-03-09 | Amgen Inc. | Recombinant dna-derived bordetella toxin subunit analogs |
US5358868A (en) * | 1987-11-24 | 1994-10-25 | Connaught Laboratories Limited | Genetic detoxification of pertussis toxin |
GB8727489D0 (en) | 1987-11-24 | 1987-12-23 | Connaught Lab | Detoxification of pertussis toxin |
US5332583A (en) * | 1987-11-24 | 1994-07-26 | Connaught Laboratories Limited | Vaccine containing genetically-detoxified pertussis holotoxin |
US5221618A (en) | 1987-11-24 | 1993-06-22 | Connaught Laboratories Limited | Genetic detoxification of pertussis toxin |
US5244657A (en) * | 1987-11-24 | 1993-09-14 | Connaught Laboratories Limited | Genetic detoxification of pertussis toxin |
JP2849632B2 (ja) | 1988-04-08 | 1999-01-20 | 社団法人北里研究所 | ワクチン製剤 |
AP8900132A0 (en) * | 1988-07-22 | 1991-01-14 | Smithkline Biolog | Bordetella pertussis vaccine |
JPH03135923A (ja) * | 1989-10-20 | 1991-06-10 | Chemo Sero Therapeut Res Inst | 百日咳毒素bオリゴマーの構成サブユニットを含有する経鼻接種ワクチン |
US5786189A (en) * | 1989-11-29 | 1998-07-28 | Smithkline Beecham Biologicals (S.A.) | Vaccine |
IT1248735B (it) * | 1990-06-21 | 1995-01-26 | Sclavo Spa | Vaccini acellulari contro la pertosse |
DE69434000T3 (de) * | 1993-10-05 | 2008-11-06 | UCB Pharma Ltd., Slough | Impfstoffzusammensetzungen |
US20030072774A1 (en) * | 1994-06-10 | 2003-04-17 | Diane M. Gajewczyk | Proteinaceous adjuvants |
US5932714A (en) * | 1995-02-23 | 1999-08-03 | Connaught Laboratories Limited | Expression of gene products from genetically manipulated strains of Bordetella |
JPH11121079A (ja) * | 1997-10-20 | 1999-04-30 | Yazaki Corp | 圧接コネクタ及び圧接コネクタの組立方法 |
US7063852B2 (en) * | 2000-05-19 | 2006-06-20 | The Administrators Of The Tulane Educational Fund | Hybrid LT-A/CT-B holotoxin for use as an adjuvant |
GB0118249D0 (en) * | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
WO2003063759A2 (en) * | 2002-01-31 | 2003-08-07 | Peptor Ltd. | Hsp peptides and analogs for modulation of immune responses via antigen presenting cells |
US6861410B1 (en) * | 2002-03-21 | 2005-03-01 | Chiron Corporation | Immunological adjuvant compositions |
-
1995
- 1995-06-07 US US08/481,878 patent/US20030072774A1/en not_active Abandoned
- 1995-06-08 PT PT95924122T patent/PT764029E/pt unknown
- 1995-06-08 DK DK01201610T patent/DK1149589T3/da active
- 1995-06-08 EP EP95924122A patent/EP0764029B2/de not_active Expired - Lifetime
- 1995-06-08 DE DE69535943T patent/DE69535943D1/de not_active Expired - Lifetime
- 1995-06-08 EP EP01201610A patent/EP1149589B1/de not_active Expired - Lifetime
- 1995-06-08 AT AT01201610T patent/ATE429928T1/de active
- 1995-06-08 ES ES01201610T patent/ES2325475T3/es not_active Expired - Lifetime
- 1995-06-08 EP EP01201598A patent/EP1149588A1/de not_active Withdrawn
- 1995-06-08 AU AU28765/95A patent/AU2876595A/en not_active Abandoned
- 1995-06-08 CA CA002192454A patent/CA2192454A1/en not_active Abandoned
- 1995-06-08 AT AT95924122T patent/ATE219686T1/de active
- 1995-06-08 US US08/750,378 patent/US7105161B1/en not_active Expired - Fee Related
- 1995-06-08 ES ES95924122T patent/ES2179105T5/es not_active Expired - Lifetime
- 1995-06-08 WO PCT/CA1995/000341 patent/WO1995034323A2/en active IP Right Grant
- 1995-06-08 DK DK95924122T patent/DK0764029T4/da active
- 1995-06-08 DE DE69527202T patent/DE69527202T3/de not_active Expired - Lifetime
- 1995-06-08 PT PT01201610T patent/PT1149589E/pt unknown
Also Published As
Publication number | Publication date |
---|---|
CA2192454A1 (en) | 1995-12-21 |
PT1149589E (pt) | 2009-07-28 |
ES2179105T5 (es) | 2008-06-16 |
EP0764029B1 (de) | 2002-06-26 |
DE69527202T3 (de) | 2008-07-31 |
EP0764029B2 (de) | 2008-03-26 |
DK0764029T4 (da) | 2008-07-28 |
WO1995034323A3 (en) | 1996-01-18 |
DK1149589T3 (da) | 2009-08-17 |
EP1149588A1 (de) | 2001-10-31 |
PT764029E (pt) | 2002-10-31 |
ATE429928T1 (de) | 2009-05-15 |
AU2876595A (en) | 1996-01-05 |
ATE219686T1 (de) | 2002-07-15 |
DK0764029T3 (da) | 2002-10-21 |
EP1149589A1 (de) | 2001-10-31 |
DE69535943D1 (de) | 2009-06-10 |
EP0764029A1 (de) | 1997-03-26 |
EP1149589B1 (de) | 2009-04-29 |
WO1995034323A2 (en) | 1995-12-21 |
ES2179105T3 (es) | 2003-01-16 |
US20030072774A1 (en) | 2003-04-17 |
DE69527202D1 (de) | 2002-08-01 |
US7105161B1 (en) | 2006-09-12 |
ES2325475T3 (es) | 2009-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69527202T2 (de) | Proteinartige adjuvantien | |
UY26801A1 (es) | Composición de vacuna | |
IS4518A (is) | Nýtt lyfjaform fyrir bóluefni | |
BR9710460A (pt) | Composi-Æo imunolÄgica multi-valente e seu uso em vacinas | |
NZ323973A (en) | Vaccine compositions for intranasal administration comprising chitosan and use thereof | |
FI970799A (fi) | Mutanttientoroksiini, joka on tehokas ei-toksinen oraalinen adjuvantti | |
DK1459766T3 (da) | Adjuvanssammensætninger til forstærkning af immunresponser på polynukleotidbaserede vacciner | |
ATE529130T1 (de) | Trockenformulierung für transkutane immunisierung | |
NO930938D0 (no) | Forbedrede vaksiner | |
AU3526995A (en) | Vaccine compositions | |
LU91154I2 (fr) | Combinaison d'anatoxine diphtérique, d'anatoxine tétanique, d'anatoxine coquelucheuse, d'hémagglutinine filamenteuse, de pertactine, de virus poliomyélitiqu inactivé type 1, type 2 et type 3 et de polyoside capsulaire d'Haemophilus influenzae type b. | |
BRPI9712917B8 (pt) | composição de vacina compreendendo toxóides diftérico, tetânico e pertussis. | |
BR0111834A (pt) | Composições adjuvante e imunogênica, e, método para eliciar uma resposta imune a um antìgeno | |
FI972054A0 (fi) | Immunogeenisiä koostumuksia | |
NO924271L (no) | Vaksiner med forbedret immunogenisitet | |
ATE329615T1 (de) | Borrelia burgdorferi bacterin | |
DK0636030T3 (da) | Pasteurella haemolytica type A-1-bacterin-toxoid-vaccine | |
DE69228063D1 (de) | Abgeschwächter rückmutierter virusimpfstoff gegen mareks krankheit serotyp-1 | |
HK1054199A1 (en) | Parenteral vaccine formulations and uses thereof | |
ECSP961797A (es) | Vacunas que comprende un antigeno conjugado polisacarido |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8363 | Opposition against the patent | ||
8366 | Restricted maintained after opposition proceedings |